Business Description
University of Cambridge Syncona Partners Llp, Cambridge Enterprise Limited
“CEGX, a pioneer in the development of epigenetic sequencing technologies and a spin-out life sciences company spun out from the University of Cambridge, was co-founded in 2012 by Professor Shankar Balasubramanian FRS and Dr. Bobby Yerramilli-Rao.
The company’s founding technology, ox-BS sequencing, allows end-users to discriminate between 5-hydroxymethylcytosine (5hmC) & 5-methylcytosine (5mC) at a single-base resolution, which was previously impossible with traditional bisulfite sequencing methods.
It has since developed a number of complementary technologies and seeks to capitalize on a wide set of applications in life sciences, as well as continue to develop breakthrough epigenetics tools.
CEGX is funded by leading VC companies GV (Google Ventures), Sequoia and Syncona and our management team comprises industry leaders and epigenetics expertise.
14.03.2016
Cambridge Epigenetix (CEGX), today announced the close of a $21 million Series B financing and the appointment of Dr. Geoff Smith as CEO. The round was led by GV (formerly Google Ventures), with significant participation from SEQUOIA CAPITAL.
Current investors NEW SCIENCE VENTURES, SYNCONA PARTNERS and CAMBRIDGE UNIVERSITY also joined the round. In conjunction with the fundraising, Tom Hulme, GV general partner, will join CEGX’s board of directors and co-founder Dr. Bobby Yerramilli-Rao will assume the role of Chairman.
New CEO Dr. Geoff Smith joins CEGX from Illumina, where he served most recently as site lead and VP of Product Development.
Prof. Shankar Balasubramanian, co-founder of CEGX previously co-founded Solexa to develop Sequencing by Synthesis which is now the basis for Illumina’s market-leading NGS technology. CEGX was founded on similarly cutting-edge, patented technology which is now in use in labs around the world and continues to form the technological backbone for breakthrough work in epigenetics.”
“CEGX, a pioneer in the development of epigenetic sequencing technologies and a spin-out life sciences company spun out from the University of Cambridge, was co-founded in 2012 by Professor Shankar Balasubramanian FRS and Dr. Bobby Yerramilli-Rao.
The company’s founding technology, ox-BS sequencing, allows end-users to discriminate between 5-hydroxymethylcytosine (5hmC) & 5-methylcytosine (5mC) at a single-base resolution, which was previously impossible with traditional bisulfite sequencing methods.
It has since developed a number of complementary technologies and seeks to capitalize on a wide set of applications in life sciences, as well as continue to develop breakthrough epigenetics tools.
CEGX is funded by leading VC companies GV (Google Ventures), Sequoia and Syncona and our management team comprises industry leaders and epigenetics expertise.
14.03.2016
Cambridge Epigenetix (CEGX), today announced the close of a $21 million Series B financing and the appointment of Dr. Geoff Smith as CEO. The round was led by GV (formerly Google Ventures), with significant participation from SEQUOIA CAPITAL.
Current investors NEW SCIENCE VENTURES, SYNCONA PARTNERS and CAMBRIDGE UNIVERSITY also joined the round. In conjunction with the fundraising, Tom Hulme, GV general partner, will join CEGX’s board of directors and co-founder Dr. Bobby Yerramilli-Rao will assume the role of Chairman.
New CEO Dr. Geoff Smith joins CEGX from Illumina, where he served most recently as site lead and VP of Product Development.
Prof. Shankar Balasubramanian, co-founder of CEGX previously co-founded Solexa to develop Sequencing by Synthesis which is now the basis for Illumina’s market-leading NGS technology. CEGX was founded on similarly cutting-edge, patented technology which is now in use in labs around the world and continues to form the technological backbone for breakthrough work in epigenetics.”
Registered Address
B400, The Trinity Building Chesterford Business Park
Little Chesterford
Saffron Walden
CB10 1XL
Little Chesterford
Saffron Walden
CB10 1XL
Contact Details
Previous Names
| Name | Period |
|---|---|
| NEWINCCO 1171 LIMITED | 2012-03-26 - 2012-04-20 |
Key Data
- Company Number
- 08005377
- Type
- Private Limited Company
- Company Age
- 8 years
- Incorporated
- March 26, 2012
- Status
- Active
- Nature of Business
- 72110 - Research and experimental development on biotechnology
- Year End
- December 31
- Accounts Due
- September 30, 2021
- Latest Accounts
- December 31, 2019
